Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, BC / ACCESS Newswire / July 30, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfur ...

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic ...

The test looks for certain proteins in the blood that indicate the immune system is responding to the disease.

Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in ...

In 2002, a study linked hormone replacement therapy to an increased risk of breast cancer, causing many women to abandon treatment, but recent data shows that for most women in menopause, the pros ...

As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

On this week's Health Matters, WVUA 23 Anchor Carlie Horn sat down with University of Alabama College of Community Health ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

In a small trial, Mass General Brigham researchers found a drug designed to treat Celiac disease supported a more rapid ...